Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Single-dose, 2-sequence, 4-period, Cross-over, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of CKD-331 in Healthy Adult Volunteers

NCT05335044 is registered in ClinicalTrials.gov with Chong Kun Dang Pharmaceutical as lead sponsor.

NCT NCT05335044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05335044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Single-dose, 2-sequence, 4-period, Cross-over, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of CKD-331 in Healthy Adult Volunteers
Lead sponsor
Chong Kun Dang Pharmaceutical
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2022
Completion date
July 12, 2022
Enrollment
47 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension and dyslipidemia